What Is Urology?
Urology is the surgical specialty focused on the urinary tract in both men and women, and the male reproductive system. Urological conditions range from common benign conditions such as kidney stones and enlarged prostate to life-threatening malignancies including prostate, kidney, and bladder cancer. Shanghai's leading urology departments — at Renji Hospital and Changhai Hospital — are among China's most experienced, offering the full spectrum of open, laparoscopic, and robotic urological surgery alongside advanced medical oncology for urological cancers.
Common Urological Conditions
- Prostate cancer — the most common cancer in men in Western countries; rising rapidly in Asia; ranges from indolent low-risk disease to aggressive metastatic cancer
- Kidney cancer (renal cell carcinoma) — often detected incidentally on imaging; clear cell RCC is the most common subtype
- Bladder cancer — the most common urological malignancy in China; urothelial carcinoma is the predominant type
- Testicular cancer — the most common solid tumor in young men aged 15–35; highly curable with appropriate treatment
- Benign prostatic hyperplasia (BPH) — non-cancerous prostate enlargement causing lower urinary tract symptoms; extremely common in men over 50
- Kidney stones (nephrolithiasis) — crystalline deposits causing severe pain and obstruction
- Urinary incontinence — stress, urge, and mixed incontinence affecting both men and women
- Male infertility — azoospermia, oligospermia, varicocele
- Adrenal tumors — pheochromocytoma, adrenocortical carcinoma, adrenal metastases
Symptoms
- Blood in the urine (hematuria) — always warrants urgent urological evaluation
- Difficulty urinating, weak stream, or incomplete bladder emptying
- Frequent or urgent urination, nocturia
- Severe flank or back pain radiating to the groin (kidney stones)
- Painless testicular lump or swelling
- Bone pain (metastatic prostate or kidney cancer)
- Elevated PSA on blood test
- Incidentally discovered kidney or adrenal mass on imaging
- Urinary incontinence or leakage
Causes & Risk Factors
- Age — prostate cancer, BPH, and bladder cancer risk increase significantly with age
- Smoking — the single most important risk factor for bladder cancer
- Obesity — associated with kidney cancer and aggressive prostate cancer
- Family history — BRCA2 mutations increase prostate cancer risk; hereditary RCC syndromes (VHL)
- Chronic dehydration — kidney stone risk
- Cryptorchidism — major risk factor for testicular cancer
- Occupational chemical exposure — aromatic amines (bladder cancer)
Diagnosis
- PSA blood test — primary screening tool for prostate cancer
- Multiparametric MRI of the prostate (mpMRI) — gold standard for prostate cancer localization; guides targeted biopsy
- MRI/ultrasound fusion-guided prostate biopsy — targeted biopsy for improved cancer detection
- Cystoscopy — direct visualization of the bladder; essential for bladder cancer diagnosis
- CT urography — comprehensive imaging of the kidneys, ureters, and bladder
- Renal mass protocol CT or MRI — for kidney tumor characterization
- PSMA PET-CT — for prostate cancer staging and recurrence detection
- Scrotal ultrasound — for testicular mass assessment
- Urodynamic studies — for incontinence and voiding dysfunction
- Semen analysis — for male infertility evaluation
Treatment Options
- Robotic-assisted radical prostatectomy (RARP) — da Vinci robotic surgery for localized prostate cancer; nerve-sparing technique preserves continence and potency
- Active surveillance — for low-risk prostate cancer; avoids overtreatment
- Novel hormonal agents — Enzalutamide, Abiraterone, Apalutamide for castration-resistant prostate cancer
- PARP inhibitors — Olaparib for BRCA-mutated prostate cancer
- PSMA-targeted radioligand therapy — Lu-177 PSMA-617 for metastatic CRPC
- Robotic partial nephrectomy — kidney-sparing surgery for small renal masses
- Targeted therapy for metastatic RCC — Cabozantinib, Sunitinib, Axitinib
- Immunotherapy for RCC — Nivolumab + Ipilimumab, Pembrolizumab + Axitinib
- TURBT — endoscopic resection for non-muscle-invasive bladder cancer
- Intravesical BCG therapy — immunotherapy for high-risk bladder cancer
- Robotic radical cystectomy — for muscle-invasive bladder cancer with urinary diversion
- HoLEP (holmium laser enucleation) — gold standard endoscopic treatment for large BPH prostates
- ESWL and ureteroscopy — for kidney stone fragmentation and removal
- PCNL — percutaneous nephrolithotomy for large or complex stones
- Orchiectomy and BEP chemotherapy — for testicular cancer; highly curative
- Sling procedures and artificial urinary sphincter — for stress urinary incontinence
Why Treat Urological Conditions in Shanghai?
- Renji Hospital and Changhai Hospital are among China's most experienced urological centers with high-volume robotic surgery programs
- da Vinci robotic platform for prostatectomy, nephrectomy, and cystectomy at a fraction of Western costs
- Access to the latest PSMA-targeted therapies, PARP inhibitors, and novel hormonal agents for advanced prostate cancer
- Comprehensive stone disease program with ESWL, ureteroscopy, and PCNL
- Treatment costs typically 60–75% lower than equivalent care in the US, UK, or Australia
- Shorter waiting times for both elective and urgent procedures
Our Specialist Network
CMCS works with leading urologists and urological oncologists across Shanghai's top hospitals, including specialists in robotic prostate surgery, kidney cancer, bladder cancer, stone disease, and male health at Renji Hospital, Changhai Hospital, and Zhongshan Hospital. We match each patient with the right specialist for their specific condition.
How CMCS Can Help
China Medical Concierge Shanghai (CMCS) coordinates comprehensive urological care for international patients — from reviewing your PSA results, imaging, and pathology reports, to arranging specialist consultations, facilitating mpMRI and targeted biopsy, coordinating robotic surgery and hospital admission, providing medical interpretation, and supporting your post-operative recovery and oncological follow-up in Shanghai.
0 comments